These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37397990)

  • 41. Establishment and characterization of a triple negative basal-like breast cancer cell line with multi-drug resistance.
    Boichuk S; Galembikova A; Sitenkov A; Khusnutdinov R; Dunaev P; Valeeva E; Usolova N
    Oncol Lett; 2017 Oct; 14(4):5039-5045. PubMed ID: 29085518
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
    Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
    Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
    Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer.
    Powell RT; Redwood A; Liu X; Guo L; Cai S; Zhou X; Tu Y; Zhang X; Qi Y; Jiang Y; Echeverria G; Feng N; Ma X; Giuliani V; Marszalek JR; Heffernan TP; Vellano CP; White JB; Stephan C; Davies PJ; Moulder S; Symmans WF; Chang JT; Piwnica-Worms H
    Sci Rep; 2020 Oct; 10(1):17899. PubMed ID: 33087803
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The depolymerizing kinesin MCAK uses lattice diffusion to rapidly target microtubule ends.
    Helenius J; Brouhard G; Kalaidzidis Y; Diez S; Howard J
    Nature; 2006 May; 441(7089):115-9. PubMed ID: 16672973
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities.
    Lanning NJ; Castle JP; Singh SJ; Leon AN; Tovar EA; Sanghera A; MacKeigan JP; Filipp FV; Graveel CR
    Cancer Metab; 2017; 5():6. PubMed ID: 28852500
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer.
    Piemonte KM; Ingles NN; Weber Bonk KL; Valentine MJ; Majmudar PR; Singh S; Keri RA
    Cancer Res; 2024 Jul; ():. PubMed ID: 39037997
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of Potential Key Genes Associated With the Pathogenesis, Metastasis, and Prognosis of Triple-Negative Breast Cancer on the Basis of Integrated Bioinformatics Analysis.
    Zhao B; Xu Y; Zhao Y; Shen S; Sun Q
    Front Oncol; 2020; 10():856. PubMed ID: 32596149
    [No Abstract]   [Full Text] [Related]  

  • 49. TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing.
    Liu T; Sun H; Zhu D; Dong X; Liu F; Liang X; Chen C; Shao B; Wang M; Wang Y; Sun B
    Mol Cancer Ther; 2017 Jul; 16(7):1377-1388. PubMed ID: 28416606
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of Cdc20 suppresses the metastasis in triple negative breast cancer (TNBC).
    Song C; Lowe VJ; Lee S
    Breast Cancer; 2021 Sep; 28(5):1073-1086. PubMed ID: 33813687
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
    Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
    BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
    [TBL] [Abstract][Full Text] [Related]  

  • 53. LEM Domain Containing 1 Acts as a Novel Oncogene and Therapeutic Target for Triple-Negative Breast Cancer.
    Li X; Jiang S; Jiang T; Sun X; Guan Y; Fan S; Cheng Y
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296887
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Paclitaxel Resistance Modulated by the Interaction between TRPS1 and AF178030.2 in Triple-Negative Breast Cancer.
    Zhao T; Zhang T; Zhang Y; Zhou B; Lu X
    Evid Based Complement Alternat Med; 2022; 2022():6019975. PubMed ID: 35399640
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
    Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
    Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer.
    Tang AH; Hoefer RA; Guye ML; Bear HD
    Cancer Drug Resist; 2022; 5(3):691-702. PubMed ID: 36176751
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.
    Wei W; Zou Y; Jiang Q; Zhou Z; Ding H; Yan L; Yang S
    Int J Biol Markers; 2018 Jan; 33(1):102-108. PubMed ID: 28623645
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.
    Cınar V; Hamurcu Z; Guler A; Nurdinov N; Ozpolat B
    Breast Cancer; 2022 Nov; 29(6):1106-1120. PubMed ID: 36006564
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antagonistic Pharmacological Interaction between Sirtuin Inhibitor Cambinol and Paclitaxel in Triple-Negative Breast Cancer Cell Lines: An Isobolographic Analysis.
    Wawruszak A; Luszczki J; Okon E; Czerwonka A; Stepulak A
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742901
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
    Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
    Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.